Genmab A/S (GMAB) News
Follow Genmab A/S (GMAB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 39 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Genmab Q3 Profit Falls as Revenue Rises; FY26 Outlook Maintained
Genmab reported net profit of $342 million, or $5.581 per share, versus $401 million, or $6.46 per share a year earlier. Revenue increased to $1.187 billion from $1.022 billion, and the company maintained its FY26 revenu
EQUITY | Nov 05, 2026, 05:33 PM UTC
M
Genmab Reports Nine-Month Revenue of $3.24 Billion, Maintains 2026 Guidance
Revenue rose 22% year over year to $3.24 billion for the nine months ended September 30, 2026. Genmab reported operating profit of $986 million and net profit of $698 million.
EARNINGS | Nov 05, 2026, 05:02 PM UTC
H
Genmab A/S (GMAB) Maintains 2026 Financial Guidance
Genmab maintained its 2026 financial guidance published August 6, 2026. The release cites late-stage program updates but provides no financial figures in the supplied text.Material DetailsContext by AI AnalystThis is an
EQUITY | Nov 05, 2026, 04:07 PM UTC
L
Genmab Reports Nine-Month 2026 Financial Results
Genmab released its interim report for the nine months ended September 30, 2026. The report highlights approval in Europe of TEPKINLY plus R(2) for second-line follicular lymphoma.
EARNINGS | Nov 05, 2026, 04:02 PM UTC
M
Genmab Shares Surge 29% to Record High on Cancer Trial Data
U.S.-listed shares rose 29% to $57.52 after trial data showed an experimental cancer therapy cut patient mortality risk by half.
EQUITY | Oct 28, 2026, 05:24 PM UTC
M
Genmab Combination Improves Survival in Phase 3 Cancer Trial
Genmab reported positive Phase 3 results for petosemtamab plus Keytruda as first-line treatment for PD-L1-positive recurrent or metastatic head and neck cancer. The combination significantly improved overall survival.
EQUITY | Oct 28, 2026, 03:54 PM UTC
M
Genmab Reports 50% Reduction in Risk of Death in Phase 3 Trial
Genmab reported positive topline results from a Phase 3 head and neck cancer trial, including a 50% reduction in risk of death.
EQUITY | Oct 28, 2026, 02:40 PM UTC
M
Genmab Shares Jump 13% After Positive Late-Stage Cancer Trial Results
Genmab said an experimental drug reduced the risk of death and disease progression for ovarian-cancer patients in a late-stage trial. Shares rose 13% in European morning trade Monday.
EQUITY | Oct 26, 2026, 10:05 AM UTC
M
Genmab Reports Phase 2 ORRs of 75% and 67% in mCRC
Genmab reported updated results for petosemtamab plus FOLFOX/FOLFIRI, with ORRs of 75% in first-line and 67% in second-line patients. ORR was 81% in first-line left-sided tumors; the data support ongoing global Phase 3 t
EQUITY | Oct 25, 2026, 11:04 AM UTC
M
Genmab Says Rinatabart Sesutecan Improves Progression-Free Survival
EQUITY | Oct 23, 2026, 04:38 PM UTC
M
Genmab Says Ovarian Cancer Drug Met Two Phase 3 Endpoints
Genmab said Rina-S significantly reduced the risk of disease progression in patients with platinum-resistant ovarian cancer.
EQUITY | Oct 23, 2026, 04:14 PM UTC
M
Genmab Phase 3 Trial of Rina-S Meets PFS and OS Endpoints
Genmab said the RAINFOL-02 trial met its progression-free and overall survival endpoints in platinum-resistant ovarian cancer. PFS hazard ratio was 0.29 in the ITT population and OS hazard ratio was 0.43; safety was cons
EQUITY | Oct 23, 2026, 03:56 PM UTC
M
Genmab Says Rina-S Shows Significant PFS and Overall Survival Improvement
Genmab announced positive topline Phase 3 results for rinatabart sesutecan in patients with platinum-resistant ovarian cancer.
EQUITY | Oct 23, 2026, 03:56 PM UTC
M
Genmab drug epcoritamab reduces lymphoma progression or death risk by 51%
Genmab and AbbVie announced that their drug epcoritamab, when added to standard treatment for newly diagnosed diffuse large B-cell lymphoma, reduced the risk of cancer worsening or death by 51% compared to standard treat
EQUITY | Oct 06, 2026, 12:11 PM UTC
M
European shares rise, Genmab jumps on drug trial results, bond yields dip
European shares climbed towards one-week highs, led by gains in healthcare stocks after Genmab announced upbeat drug-trial results. Euro zone bond yields stabilized after recent gains driven by fiscal and inflation conce
MACRO | Oct 06, 2026, 08:51 AM UTC
M
Genmab Shares Climb on Positive Blood-Cancer Drug Study Results
Genmab shares jumped 8.3% after the company and partner AbbVie announced positive late-stage clinical trial results for their Epkinly drug in a common type of lymphoma. The drug helped extend the time patients lived with
EQUITY | Oct 06, 2026, 08:11 AM UTC
M
STOXX 600 Rises, Driven by Healthcare Gains
Europe's STOXX 600 index (SXXP) is up 0.8%, with significant gains led by healthcare companies. Biotech firm Genmab (GMAB) is a top performer, jumping over 8% to reach a new high.
EQUITY | Oct 06, 2026, 07:55 AM UTC
M
AbbVie, Genmab drug combo shows improved PFS in DLBCL trial
AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial of epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The combination d
EQUITY | Oct 06, 2026, 05:34 AM UTC
M
Genmab and AbbVie blood cancer drug combo cuts risk of progression or death
Danish biotech firm Genmab and US drugmaker AbbVie announced that their combination treatment for newly diagnosed patients with a type of lymphoma reduced the risk of disease progression or death in a late-stage study. S
EQUITY | Oct 05, 2026, 10:09 PM UTC
H
AbbVie, Genmab drug combo cuts lymphoma progression or death risk in study
AbbVie (ABBV) and Genmab (GMAB) reported that their combination treatment for newly diagnosed lymphoma patients reduced the risk of disease progression or death in a late-stage study. The news sent Genmab shares up about
EQUITY | Oct 05, 2026, 07:36 PM UTC
M
Genmab Drug Combo Cuts DLBCL Progression/Death Risk by 51% in Phase 3
Genmab reported topline Phase 3 data showing epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed DLBCL patients.
EQUITY | Oct 05, 2026, 06:50 PM UTC
H
Genmab, AbbVie drug shows PFS improvement in DLBCL trial
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial. The trial evaluated fixed treatment duration epcoritamab in combination with rituximab and standard of care, demonstrating a sta
EQUITY | Oct 05, 2026, 06:50 PM UTC
L
Weekly Recap: Q4 2026 Phase III readouts and RSU/warrant grants
Genmab A/S Sponsored ADR (OMXCOP:GMAB) is gearing for potential 2027 launches after pivotal Phase III readouts for Rina-S, petosemtamab and EPKINLY expected in Q4 2026, while granting employees 13,794 RSUs and 13,331 war
NEWS | Sep 28, 2026, 05:01 AM UTC
L
GMAB: Late-stage pipeline advances and strong growth set up major Q4 data readouts in oncology
Multiple late-stage assets are advancing, with six new phase III trials and strong financial growth. Petosemtamab and EPKINLY are poised for major data readouts in Q4, potentially setting new standards in head and neck,
NEWS | Sep 15, 2026, 02:08 PM UTC
L
GMAB: Late-stage pipeline advances and strong financials set up multiple key data readouts in Q4
Significant pipeline progress includes nine revenue-generating medicines, six new phase III trials, and strong financial growth. Petosemtamab and EPKINLY are advancing in late-stage trials, with multiple data readouts ex
EARNINGS | Sep 15, 2026, 01:32 PM UTC
L
Weekly Recap: Epcoritamab Phase III readout and DKK 44.3m share issuance
Genmab A/S Sponsored ADR (OMXCOP:GMAB) said a pivotal Phase III readout for epcoritamab in first-line DLBCL is due next quarter while the company issued 28,011 new shares after employee warrant exercises, raising ~DKK 44
EQUITY | Sep 14, 2026, 05:15 AM UTC
L
GMAB: Three key phase III oncology readouts are imminent, targeting major commercial opportunities
Three major phase III readouts are expected next quarter, including pivotal data for epcoritamab in first-line DLBCL, petosemtamab in head and neck cancer, and Rina-S in PROC. Epcoritamab and petosemtamab are positioned
EQUITY | Sep 09, 2026, 09:55 PM UTC
L
GMAB: Major phase III data for three assets expected next quarter, targeting broad first-line markets
Three major phase III assets are set for key data readouts next quarter, with epcoritamab, petosemtamab, and Rina-S targeting significant first-line and expansion opportunities. Epcoritamab's label updates and new indica
EQUITY | Sep 09, 2026, 08:18 PM UTC
L
Genmab to increase share capital via employee warrant exercise
Genmab A/S will increase its share capital by 28,011 shares following the exercise of employee warrants. The increase will be effected without preemption rights for existing shareholders or others.
EQUITY | Sep 08, 2026, 06:47 PM UTC
L
Genmab to convene extraordinary general meeting on Oct 7, 2026
Genmab A/S will convene an Extraordinary General Meeting on Wednesday, October 7, 2026, at 3:00 PM CEST at its offices on Carl Jacobsens Vej 30, 2500 Valby, Denmark.
EQUITY | Sep 08, 2026, 10:07 AM UTC
L
Genmab Raises FY2026 Sales Guidance from $4.065B-$4.395B to $4.325B-$4.525B vs $4.355B Est
Genmab (NASDAQ: GMAB ) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billion-$4.525 billion vs $4.355 billion estimate.
EARNINGS | Aug 06, 2026, 07:52 PM UTC
H
CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Truist upgraded CoreWeave (CRWV) t
MNA | Jul 22, 2026, 01:46 PM UTC
L
GMAB upgraded from Hold to Buy W/ $43 PT (from $32) @ TDCowen
GMAB upgraded from Hold to Buy W/ $43 PT (from $32) @ TDCowen
EQUITY | Jul 22, 2026, 12:19 PM UTC
L
GMAB Upgrade from Hold to Buy W/$43.00 PT (from $32.00) at TD Cowen
GMAB Upgrade from Hold to Buy W/$43.00 PT (from $32.00) at TD Cowen
EQUITY | Jul 22, 2026, 12:02 PM UTC
L
GMAB Genmab announces net sales of darzalex® (daratumumab) for second quarter of 2026 Genmab - net sales of darzalex in Q2 of 2026 totaled U
GMAB Genmab announces net sales of darzalex® (daratumumab) for second quarter of 2026 Genmab - net sales of darzalex in Q2 of 2026 totaled USD 4,207M - Q2 darzalex net trade sales were USD 2,435M in U.S. and USD 1,772M i
FX | Jul 15, 2026, 10:23 AM UTC
L
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ: GMAB ) with a Buy and raises the price target from $38 to $40.
EQUITY | Jul 02, 2026, 11:05 AM UTC
L
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Genmab A/S – ADR (NASDAQ: GMAB ) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, r
EARNINGS | Jun 30, 2026, 04:31 PM UTC
H
Select Premarket Movers
Upside: -AVAV +35% (earnings, guidance) -VWAV +29% (acquires 51% controlling interest in private Israeli aerospace and defense company Meteor Aerospace for ~$20.4M in stock) -SEDG +11% (solar stock strength following FCC
GEOPOLITICS | Jun 30, 2026, 12:26 PM UTC
H
Market-Moving News for June 30th
AVAV: 31% | AeroVironment shares are trading higher after the company reported better-than-expected Q4 financial results. GMAB: 8% | Genmab shares are trading higher after the company announced topline results from the P
EARNINGS | Jun 30, 2026, 11:13 AM UTC